<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05071222</url>
  </required_header>
  <id_info>
    <org_study_id>D20180302</org_study_id>
    <secondary_id>2019-003555-11</secondary_id>
    <nct_id>NCT05071222</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE)</brief_title>
  <acronym>ARTEGENE</acronym>
  <official_title>A Phase 1/2 Open Label Non Randomized Study, Multicentric, Single Arm Evaluating the Safety and Efficacy of Gene Therapy of the Severe Combined Immunodeficiency (SCID) Caused by Mutations in the Human DCLRE1C Gene (Artemis) by Transplantation of a Single Dose of Autologous CD34+ Cells Transduced ex Vivo With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Safety and Efficacy of Gene Therapy of the&#xD;
      severe combined immunodeficiency (SCID) caused by mutations in the human DCLRE1C gene&#xD;
      (Artemis) by transplantation of a single dose of autologous CD34+ cells transduced ex vivo&#xD;
      with the G2ARTE lentiviral vector expressing the DCLRE1C cDNA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2039</completion_date>
  <primary_completion_date type="Anticipated">October 2039</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of transplant related mortality</measure>
    <time_frame>Up to 100 days post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of transplant related mortality</measure>
    <time_frame>At 6 months post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Transgene copy number on peripheral blood mononuclear cells (PBMCs)</measure>
    <time_frame>Up to 15 years post treatment</time_frame>
    <description>by qPCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Transgene copy number on sorted cell populations</measure>
    <time_frame>Up to 15 years post treatment</time_frame>
    <description>Determined on sorted cell populations CD15+,CD14+, CD19+, CD56+ and CD3+ T lymphocytes by qPCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection of replication-competent lentivirus (RCL)</measure>
    <time_frame>3 months post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Absence of any severe adverse events due to insertional mutagenesis</measure>
    <time_frame>Up to 15 years post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Artemis mRNA levels</measure>
    <time_frame>At Day 0, 12 months and 24 months post treatment</time_frame>
    <description>by RT-qPCR performed on the transduced CD34+ cells in the drug substance and on peripheral blood mononuclear cells (PBMC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 15 years post treatment</time_frame>
    <description>Frequency and severity of clinical AEs and changes in laboratory parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Transgene copy number in the transduced CD34+ cells in the drug substance</measure>
    <time_frame>At Day 0</time_frame>
    <description>by qPCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in total number of T cells</measure>
    <time_frame>6, 12, 24 months post treatment</time_frame>
    <description>by flow cytometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in distribution of different subpopulations</measure>
    <time_frame>6, 12, 24 months post treatment</time_frame>
    <description>by flow cytometry, according to the WBC count: Naïve and activated/memory CD4+ and CD8+ T cells will be evaluated using CCR7/CD45RA/CD45RO markers. Early thymic emigrants will be monitored by detecting CD31+CD45RA+CD4+ T lymphocytes; Stem cell-like memory CD8+ and CD4+ T cells will be quantified by counting CCR7+CD45RA+CD8+ T cells. Evaluation of the distribution of TCRαβ and TCRγδ T cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in T lymphocyte in vitro proliferation in the presence of mitogens and antigens</measure>
    <time_frame>6, 12, 24 months post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in repertoire of T lymphocytes</measure>
    <time_frame>12, 24 months post treatment</time_frame>
    <description>via high-throughput sequencing of the TCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the B lymphocyte compartment</measure>
    <time_frame>6 months post treatment</time_frame>
    <description>analysis of the circulating B cell subpopulations by flow cytometry: total CD19+ cells, naive (CD19+IgD+CD27-), switched memory (CD19+IgD-CD27+), marginal zone (CD19+IgD+CD27+), transitional (CD19+IgD+CD27-CD24highCD38+), 21low (CD19+CD38-CD21low). Immunoglobulin levels (IgG, A, M and E) and specific antibody production after immunization (if applicable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the B lymphocyte compartment</measure>
    <time_frame>At 12 months post treatment</time_frame>
    <description>analysis of the circulating B cell subpopulations by flow cytometry: total CD19+ cells, naive (CD19+IgD+CD27-), switched memory (CD19+IgD-CD27+), marginal zone (CD19+IgD+CD27+), transitional (CD19+IgD+CD27-CD24highCD38+), 21low (CD19+CD38-CD21low). Immunoglobulin levels (IgG, A, M and E) and specific antibody production after immunization (if applicable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the B lymphocyte compartment</measure>
    <time_frame>At 24 months post treatment</time_frame>
    <description>analysis of the circulating B cell subpopulations by flow cytometry: total CD19+ cells, naive (CD19+IgD+CD27-), switched memory (CD19+IgD-CD27+), marginal zone (CD19+IgD+CD27+), transitional (CD19+IgD+CD27-CD24highCD38+), 21low (CD19+CD38-CD21low). Immunoglobulin levels (IgG, A, M and E) and specific antibody production after immunization (if applicable)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>End of ongoing infection before the transplantation</measure>
    <time_frame>Up to 15 years post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kinetics of immune reconstitution</measure>
    <time_frame>Up to 15 years post treatment</time_frame>
    <description>Kinetics of immune reconstitution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>Up to 15 years post treatment</time_frame>
    <description>Adverse event will be measured using CTCAE</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency</condition>
  <arm_group>
    <arm_group_label>ARTEGENE drug product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous purified CD34+ cells transduced with a self-inactivated lentiviral vector, expressing the DCLRE1C gene (alias Artemis)</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>ARTEGENE drug product</intervention_name>
    <description>Each patient will receive a single intravenous infusion of ARTEGENE drug product at D0.</description>
    <arm_group_label>ARTEGENE drug product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient less than one year&#xD;
&#xD;
          -  SCID patients with confirmed biallelic mutations in the Artemis (DCLRE1C) gene&#xD;
&#xD;
          -  Absence of an HLA genoidentical donor or without rapidly available HLA-compatible&#xD;
             unrelated donor (within six weeks of diagnosis)&#xD;
&#xD;
          -  The patient can be treated by gene therapy without delay in case of active life&#xD;
             threatening infections compromising the short-term prognosis and for which the delay&#xD;
             in finding a phenoidentical donor is incompatible with the patient's condition of&#xD;
             health. Active life threatening infections are defined as: viral respiratory&#xD;
             infection, CMV infection, adenovirus infection, disseminated BCGitis or other&#xD;
             infections grade ≥ 4 according to CTCAE scale&#xD;
&#xD;
          -  Parental, guardian's patient signed informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Unwillingness to return for follow-up during the first 2 years study and the long term&#xD;
             follow-up&#xD;
&#xD;
          -  HIV-1 or 2 or HTLV1 infections&#xD;
&#xD;
          -  Hypersensitivity to nivestim or busulfan&#xD;
&#xD;
          -  Unable to tolerate general anesthesia and/or marrow harvest or peripheral blood stem&#xD;
             cell collection (apheresis) or insertion of central venous catheter.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandra MAGNANI, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Biotherapy,LTCG, Necker-Enfants Malades Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chantal Lagresle-Peyrou, MD</last_name>
    <role>Study Director</role>
    <affiliation>IMAGINE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marina CAVAZZANA, MD, PhD</last_name>
    <phone>+33 144495068</phone>
    <email>m.cavazzana@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valérie JOLAINE, Master</last_name>
    <phone>+33 1 42 19 28 79</phone>
    <email>valerie.jolaine@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Pediatric Immunology, Hematology and Rheumatology UIHR, Necker-Enfants Malades Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Despina MOSHOUS, MD, PhD</last_name>
      <email>despina.moshous@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Artemis deficient Severe Combined Immunodeficiency</keyword>
  <keyword>Severe Combined Immunodeficiency</keyword>
  <keyword>Gene therapy</keyword>
  <keyword>Allogeneic hematopoietic stem cells transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Severe Combined Immunodeficiency</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

